First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study
暂无分享,去创建一个
G. Follows | A. Kater | L. Ysebaert | T. Robak | M. Šimkovič | A. Österborg | C. Niemann | A. Steele | M. Levin | C. Owen | A. Janssens | D. Stevens | O. Benjamini | S. Voloshin | C. Moreno | V. Vorobyev | K. Baeten | N. Schuier | T. Munir | Munchi Yagci | Qianaya Qi | Donne Bennett Caces